Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Global Cancer Monoclonal Antibodies Market to Cross ~USD 157 Billion Mark by 2030 | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Sep 02, 2024, 17:46 ET

      Share this article

      Share this article


      The increasing demand for cancer monoclonal antibodies is mainly driven by the rising incidence of cancer, the growing prevalence of risk factors like smoking, radiation exposure, unhealthy lifestyles, and other contributing factors. Additionally, the surge in research and development activities by market players is expected to further fuel this demand throughout the forecast period from 2024 to 2030.

      LAS VEGAS, Sept. 2, 2024 /PRNewswire/ -- DelveInsight's Cancer Monoclonal Antibodies Market Insights report provides the current and forecast market analysis, individual leading cancer monoclonal antibodies companies' market shares, challenges, cancer monoclonal antibodies market drivers, barriers, trends, and key market cancer monoclonal antibodies companies in the market.

      Key Takeaways from the Cancer Monoclonal Antibodies Market Report

      • As per DelveInsight estimates, North America is anticipated to dominate the global cancer monoclonal antibodies market during the forecast period. 
      • In the application segment of the cancer monoclonal antibodies market, the breast cancer category had a significant revenue share in the cancer monoclonal antibodies market in 2023.
      • Notable cancer monoclonal antibodies companies such as GSK plc, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson and Johnson Services Inc., Spectrum Pharmaceuticals Inc., Eurofins Scientific, Genmab AS, Bristol Myers Squibb Company, Elli Lilly and Company, Amgen, Inc., AbbVie Inc., AstraZeneca Plc., CStone Pharmaceuticals, HiFiBiO Therapeutics, and several others, are currently operating in the cancer monoclonal antibodies market.
      • In April 2024, CE approved the VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU® (trastuzumab deruxtecan) may be considered as a targeted treatment.
      • In December 2023, CStone Pharmaceuticals announced that the National Medical Products Administration (NMPA) of China approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly®) in combination with fluorouracil and platinum-based chemotherapy as first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). Sugemalimab became the world's first anti-PD-L1 monoclonal antibody approved for the first-line ESCC indication.

      To read more about the latest highlights related to the cancer monoclonal antibodies market, get a snapshot of the key highlights entailed in the Global Cancer Monoclonal Antibodies Market Report

      Cancer Monoclonal Antibodies Overview

      Monoclonal antibodies (mAbs) have revolutionized cancer treatment by offering highly targeted therapies that specifically attack cancer cells while sparing healthy tissue. These antibodies are laboratory-made molecules designed to bind to specific antigens on the surface of cancer cells. By recognizing these unique markers, monoclonal antibodies can interfere with the growth and spread of cancer in several ways. For example, they can block signals that stimulate cancer cell proliferation, mark cancer cells for destruction by the immune system, or deliver toxic substances directly to the cancer cells. This specificity reduces the side effects typically associated with conventional chemotherapy and radiation, making mAbs an essential component of modern oncology.

      There are several types of monoclonal antibodies used in cancer treatment, including naked mAbs, which work by themselves, and conjugated mAbs, which are linked to drugs or radioactive particles. Some well-known examples include Rituximab, used in the treatment of certain types of lymphoma, and Trastuzumab, which targets HER2-positive breast cancer. These therapies have shown significant success in improving survival rates and quality of life for many patients. However, challenges remain, such as the development of resistance by cancer cells and the high cost of production. Ongoing research aims to overcome these hurdles by developing more effective and affordable mAbs, as well as combining them with other treatments to enhance their efficacy.

      Cancer Monoclonal Antibodies Market Insights

      North America held the largest share of the cancer monoclonal antibodies market in 2023, driven by several factors. The region's leading position is attributed to the rising incidence of cancers, greater exposure to carcinogens such as smoking, radiation, and viruses, and recent regulatory approvals that favor the growth of the cancer monoclonal antibodies market in North America.

      Furthermore, the increasing number of regulatory approvals for these antibodies is expected to further stimulate market growth. For instance, in October 2022, the FDA approved the combination of durvalumab (IMFINZI), a human monoclonal antibody, with the experimental drug tremelimumab for treating unresectable hepatocellular carcinoma.

      The large patient population in North America is likely to drive demand for cancer monoclonal antibodies, leading to market expansion in the coming years. Therefore, the combined influence of these factors is expected to contribute significantly to the growth of the cancer monoclonal antibodies Market in North America from 2024 to 2030.

      To know more about why North America is leading the market growth in the cancer monoclonal antibodies market, get a snapshot of the Cancer Monoclonal Antibodies Market Outlook 

      Cancer Monoclonal Antibodies Market Dynamics

      The global market for cancer monoclonal antibodies has experienced significant growth over the past decade, driven by the increasing incidence of cancer, advancements in biotechnology, and the rising demand for targeted therapies. Monoclonal antibodies, which are designed to specifically target cancer cells while sparing healthy tissue, have become a cornerstone in the treatment of various cancers. Their specificity and reduced side effects compared to traditional chemotherapy have made them an attractive option for both patients and healthcare providers.

      One of the key dynamics shaping the cancer monoclonal antibodies market is the ongoing innovation in antibody engineering. Techniques such as antibody-drug conjugates, bispecific antibodies, and immune checkpoint inhibitors have expanded the therapeutic potential of mAbs, leading to the development of more effective and versatile cancer treatments. These innovations have not only enhanced the efficacy of existing therapies but have also opened up new avenues for addressing previously untreatable or resistant forms of cancer.

      The competitive landscape of the market is also influenced by the expiration of patents on several blockbuster mAbs, paving the way for biosimilars to enter the market. Biosimilars, which are essentially generic versions of biologic drugs, offer similar efficacy at a lower cost, making cancer treatment more accessible. However, the introduction of biosimilars has also intensified competition among pharmaceutical companies, driving the need for continuous innovation and the development of next-generation therapies to maintain market share.

      Regulatory and reimbursement challenges also play a crucial role in the market dynamics. The stringent regulatory requirements for the approval of mAbs, coupled with the high costs associated with their development and manufacturing, can pose barriers to market entry. Additionally, securing favorable reimbursement from healthcare systems is critical for the widespread adoption of these therapies. As healthcare budgets become increasingly strained, especially in the wake of the COVID-19 pandemic, the cost-effectiveness of mAbs will likely be a focal point in discussions between pharmaceutical companies, regulators, and payers.

      In conclusion, the cancer monoclonal antibodies market is poised for continued growth, driven by technological advancements, the entry of biosimilars, and the rising demand for personalized cancer therapies. However, the market will need to navigate challenges related to regulation, competition, and cost-effectiveness to sustain its momentum. As research and development in the field of immuno-oncology continue to advance, the landscape of cancer treatment is likely to evolve, offering new hope for patients and further solidifying the role of monoclonal antibodies in cancer care.

      Get a sneak peek at the cancer monoclonal antibodies market dynamics @ Cancer Monoclonal Antibodies Market Dynamics Analysis

      Report Metrics

      Details

      Coverage

      Global

      Study Period

      2021–2030

      Cancer Monoclonal Antibodies Market CAGR

      ~10%

      Cancer Monoclonal Antibodies Market Size by 2030

      ~USD 157 Billion

      Key Cancer Monoclonal Antibodies Companies

      GSK plc, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson and Johnson Services Inc., Spectrum Pharmaceuticals Inc., Eurofins Scientific, Genmab AS, Bristol Myers Squibb Company, Elli Lilly and Company, Amgen, Inc., AbbVie Inc., AstraZeneca Plc., CStone Pharmaceuticals, HiFiBiO Therapeutics, among others

      Cancer Monoclonal Antibodies Market Assessment

      • Cancer Monoclonal Antibodies Market Segmentation
        • Cancer Monoclonal Antibodies Market Segmentation By Type: Humanized Antibodies, Chimeric Antibodies, Murine Antibodies
        • Cancer Monoclonal Antibodies Market Segmentation By Application: Blood Cancer, Breast Cancer, Liver Cancer, Colorectal Cancer, and Others
        • Cancer Monoclonal Antibodies Market Segmentation By End Users: Hospitals, Research Institutions & Laboratories, and Others
        • Cancer Monoclonal Antibodies Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
      • Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

      Which MedTech key players in the cancer monoclonal antibodies market are set to emerge as the trendsetter explore @ Cancer Monoclonal Antibodies Companies 

      Table of Contents 

      1

      Cancer Monoclonal Antibodies Market Report Introduction

      2

      Cancer Monoclonal Antibodies Market Executive Summary

      3

      Competitive Landscape

      4

      Regulatory Analysis

      5

      Cancer Monoclonal Antibodies Market Key Factors Analysis

      6

      Cancer Monoclonal Antibodies Market Porter's Five Forces Analysis

      7

      Cancer Monoclonal Antibodies Market Layout

      8

      Cancer Monoclonal Antibodies Market Company and Product Profiles

      9

      KOL Views

      10

      Project Approach

      11

      About DelveInsight

      12

      Disclaimer & Contact Us

      Interested in knowing the cancer monoclonal antibodies market by 2030? Click to get a snapshot of the Cancer Monoclonal Antibodies Market Trends

      Related Reports

      Monoclonal Antibodies Competitive Landscape

      Monoclonal Antibodies Competitive Landscape – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key monoclonal antibodies companies, including Novartis, Novartis, Gmax Biopharm, Omeros Corporation, Merck Sharp & Dohme, Disc Medicine, Eledon Pharmaceuticals, Alexion AstraZeneca Rare Disease, Chinook Therapeutics, Omeros Corporation, Novo Nordisk, Merck KGaA, Bristol-Myers Squibb, Jacobio Pharmaceuticals, Nectin Therapeutics Ltd, Y-mAbs Therapeutics,  OncoResponse, Inc., Fate Therapeutics, Pelican Therapeutics, Inc., Heat Biologics, Oncternal Therapeutics, Phanes Therapeutics, Pharmacyclics LLC, Immunitas Therapeutics, Hummingbird Bioscience, Inc., Sanofi, Takeda, Agenus Inc., Aulos Bioscience, Inc., ChemomAb Ltd, Celldex Therapeutics, Celgene, Janssen Research & Development, LLC, Adaptive Biotechnologies, BeiGene, Vaccinex Inc., Jasper Therapeutics, Inc., Shanghai Junshi Bioscience Co., Ltd., TopAlliance Biosciences, Inc., among others.

      Cancer Therapy Market

      Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others.

      Oncology Drugs Market

      Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, among others.

      Non-small Cell Lung Cancer Market

      Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

      Contact Us
      Shruti Thakur
      [email protected]
      +14699457679
      https://www.delveinsight.com/medical-devices 

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.